Q3 2024 Earnings Conference Call

November 7, 2024 - 4:30 PM ET

Dial-in: 1-800-717-1738
International Dial-in: 1-646-307-1865
Conference Code: 1101650

HeartBeam AIMI™ and AIMIGo™ have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies.

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The Company holds 13 US and 4 international issued patents related to technology enablement.

View Management Team View Board of Directors

Investor Contact Information

Company

HeartBeam, Inc.
2118 Walsh Avenue
Suite 210
Santa Clara, CA 95050
T: 408-899-4443

Investor Relations

MZ North America
Chris Tyson
Executive Vice President
T: 949-491-8235
BEAT@mzgroup.us

Transfer Agent

VStock Transfer
18 Lafayette Place
Woodmere, NY 11598